Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ZSAN
CUSIPN/A
Phone510-745-1200
Debt
Debt-to-Equity RatioN/A
Current Ratio0.52
Quick Ratio0.52
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$310,000.00
Price / Sales153.29
Cash FlowN/A
Price / CashN/A
Book Value$3.57 per share
Price / Book1.11
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-29,100,000.00
Net MarginsN/A
Return on Equity-479.82%
Return on Assets-179.23%
Miscellaneous
Employees51
Outstanding Shares11,970,000
Market Cap$49.81 million
Zosano Pharma (NASDAQ:ZSAN) Frequently Asked Questions
What is Zosano Pharma's stock symbol?
Zosano Pharma trades on the NASDAQ under the ticker symbol "ZSAN."
When did Zosano Pharma's stock split? How did Zosano Pharma's stock split work?
Zosano Pharma's stock reverse split before market open on Friday, January 26th 2018. The 1-20 reverse split was announced on Thursday, January 25th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2018. An investor that had 100 shares of Zosano Pharma stock prior to the reverse split would have 5 shares after the split.
How were Zosano Pharma's earnings last quarter?
Zosano Pharma Corp (NASDAQ:ZSAN) announced its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported ($0.75) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.89) by $0.14. View Zosano Pharma's Earnings History.
When is Zosano Pharma's next earnings date?
What is the consensus analysts' recommendation for Zosano Pharma?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zosano Pharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zosano Pharma.
Who are some of Zosano Pharma's key competitors?
Some companies that are related to Zosano Pharma include Synlogic (SYBX), Galmed Pharmaceuticals (GLMD), AcelRx Pharmaceuticals (ACRX), Neos Therapeutics (NEOS), Galectin Therapeutics Inc. Common Stock (GALT), VERONA PHARMA P/S (VRNA), Menlo Therapeutics (MNLO), Avadel Pharmaceuticals (AVDL), Tocagen (TOCA), MannKind (MNKD), Mustang Bio (MBIO), Nature's Sunshine Products Common Stock (NATR), BioDelivery Sciences International (BDSI), Tetraphase Pharmaceuticals (TTPH) and Immune Design (IMDZ).
Who are Zosano Pharma's key executives?
Zosano Pharma's management team includes the folowing people:
- Mr. John P. Walker, Chairman, CEO & Pres (Age 69)
- Dr. Donald J. Kellerman, VP of Clinical Devel. & Medical Affairs (Age 63)
- Mr. Eric Scharin, VP of Operations & Engineering (Age 52)
- Ms. Hayley Lewis, Sr. VP of Operations (Age 42)
- Dr. Thorsten von Stein M.D., Ph.D., Chief Medical Officer (Age 56)
When did Zosano Pharma IPO?
(ZSAN) raised $47 million in an initial public offering (IPO) on Tuesday, January 27th 2015. The company issued 4,300,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO.
Has Zosano Pharma been receiving favorable news coverage?
Headlines about ZSAN stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zosano Pharma earned a media and rumor sentiment score of 0.19 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 47.52 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for Zosano Pharma.
Who are Zosano Pharma's major shareholders?
Zosano Pharma's stock is owned by many different of retail and institutional investors. Top institutional investors include First Republic Investment Management Inc. (0.58%), FNY Investment Advisers LLC (0.40%), CIBC Private Wealth Group LLC (0.27%) and BlackRock Inc. (0.23%). Company insiders that own Zosano Pharma stock include Amzak Capital Management, Llc, Enterprise Associates 12 New, Georgia Erbez, John Peter Walker, Kenneth Greathouse and M James Barrett. View Institutional Ownership Trends for Zosano Pharma.
Which major investors are buying Zosano Pharma stock?
ZSAN stock was bought by a variety of institutional investors in the last quarter, including First Republic Investment Management Inc., FNY Investment Advisers LLC, CIBC Private Wealth Group LLC and BlackRock Inc.. Company insiders that have bought Zosano Pharma stock in the last two years include Georgia Erbez, John Peter Walker and Kenneth Greathouse. View Insider Buying and Selling for Zosano Pharma.
How do I buy shares of Zosano Pharma?
Shares of ZSAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zosano Pharma's stock price today?
One share of ZSAN stock can currently be purchased for approximately $3.97.
How big of a company is Zosano Pharma?
Zosano Pharma has a market capitalization of $49.81 million and generates $310,000.00 in revenue each year. Zosano Pharma employs 51 workers across the globe.
How can I contact Zosano Pharma?
Zosano Pharma's mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The biotechnology company can be reached via phone at 510-745-1200 or via email at [email protected]
MarketBeat Community Rating for Zosano Pharma (NASDAQ ZSAN)
MarketBeat's community ratings are surveys of what our community members think about Zosano Pharma and other stocks. Vote "Outperform" if you believe ZSAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZSAN will underperform the S&P 500 over the long term. You may vote once every thirty days.
